Related Experiment Video

Updated: Jul 13, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

[Levosimendan-long-term inodilation in an infant with myocardial infarction]

Y C Luther1, I Schulze-Neick, B Stiller

  • 1Abteilung für Angeborene Herzfehler, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

Zeitschrift Fur Kardiologie
|March 17, 2004
PubMed

Insights

Levosimendan effectively treated refractory pulmonary hypertension (PHT) in an infant with myocardial infarction. This inodilator improved cardiac function and reduced PHT crises, suggesting its potential for pediatric heart failure.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Pharmacology

Background:

  • Congenital left coronary artery stenosis can lead to myocardial infarction, left ventricular dysfunction, and mitral regurgitation in infants.
  • Refractory pulmonary hypertension (PHT) and recurrent crises pose significant challenges in managing such pediatric cardiac conditions.

Observation:

  • An infant presented with myocardial infarction, severe left ventricular dysfunction, mitral regurgitation, and refractory PHT unresponsive to catecholamines and inhaled nitric oxide.
  • The patient experienced recurrent episodes of pulmonary hypertension crises.

Findings:

  • Treatment with Levosimendan, an inodilator with inotropic and vasodilating properties, demonstrated significant clinical improvement.
  • Levosimendan enhanced left ventricular function, increased cardiac index, reduced pulmonary vascular resistance, and decreased the frequency and severity of PHT crises.

Implications:

  • Levosimendan may be a valuable therapeutic option for managing pediatric patients with depressed cardiac function and pulmonary hypertension.
  • This case highlights the potential of Levosimendan as a long-term treatment strategy in complex pediatric cardiovascular diseases.

More Related Videos

Myocardial Infarction in Neonatal Mice, A Model of Cardiac Regeneration07:48

Myocardial Infarction in Neonatal Mice, A Model of Cardiac Regeneration

Published on: May 24, 2016

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...